ESSA Pharma

EPIX

Börsenwert 9,5 Mio. $

SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada , Oct. 6, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") is pleased to announce that its Securityholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the "Common Shares" and the holders of such Common Shares, the "Shareholders") by XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company, by way of a statutory plan of arrangement (the "Transaction" or the "Arrangement") at the special meeting of Securityholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 99.83% of the votes cast by Shareholders present in person or represented by proxy at the Meeting, (ii) 99.85% of the votes cast by Shareholders, holders of options to purchase Common Shares of the Company, holders of pre-funded Common Share purchase warrants of the Company (collectively, the "Securityholders"), present in person or represented by proxy at the Meeting, voting together as a single class, and (iii) 99.48% of the votes cast by Shareholders, present in person or represented by proxy at the Meeting, excluding for this purpose the votes required to be excluded pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions.

ESSA Pharma Inc. (NASDAQ:EPIX ) Shareholder/Analyst Call October 3, 2025 5:00 PM EDT Company Participants David Parkinson - President, CEO & Director David Wood - Chief Financial Officer Conference Call Participants Dave Bains Presentation Operator Hello, and welcome to the Special Meeting of Security Holders of ESSA Pharma, Inc. Please note that the meeting is being recorded. I'd like to introduce David Parkinson, President and Chief Executive Officer of ESSA.

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept.

Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting to October 3, 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept.

Adjournment to provide time for continued discussions regarding possible revised financial terms of transaction with XenoTherapeutics SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept.

SOUTH SAN FRANCISCO, Calif and VANCOUVER, BC , Aug. 25, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) announced on August 14, 2025 that, in connection with the Company's previously announced return of capital distribution in the aggregate amount of US$80,000,000 (the "Distribution") to the holders of common shares of the Company ("Common Shares" and the holders of such Common Shares, the "Shareholders") as part of the discontinuance and winding-up of the business of the Company pursuant to the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Common Shares (the "Transaction"), the Nasdaq Stock Market LLC ("Nasdaq") had determined that the ex-dividend date for the Distribution would be August 25, 2025 (the "Ex-Dividend Date"), the first business day after the payment date. The Distribution was paid to Shareholders on August 22, 2025 and Shareholders received approximately $1.6910318 per Common Share in the Distribution (subject to applicable withholding).

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Aug. 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with the Company's recently announced return of capital distribution in the aggregate amount of US$80,000,000 (the "Distribution") to the holders of common shares of the Company ("Common Shares" and the holders of such Common Shares, the "Shareholders") as part of the discontinuance and winding-up of the business of the Company pursuant to the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Common Shares (the "Transaction"), the Nasdaq Stock Market LLC ("Nasdaq") has determined that the ex-dividend date for the Distribution will be August 25, 2025 (the "Ex-Dividend Date"), the first business day after the payment date.

SOUTH SAN FRANCISCO, Calif and VANCOUVER, Canada , Aug. 6, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, following the Company's receipt of an order from the Supreme Court of British Columbia (the "Court") on August 5, 2025, authorizing a reduction in the capital of the common shares of the Company (the "Common Shares" and the holders of such Common Shares, the "Shareholders") and concurrent distribution to the Shareholders, the board of directors of the Company (the "Board") has approved a return of capital distribution in the aggregate amount of US$80,000,000 (the "Distribution") to the Shareholders as part of the discontinuance and winding-up of the business of the Company. The Distribution is scheduled to be paid on August 22, 2025, to Shareholders of record as of the close of business on August 19, 2025.

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 23, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with its previously announced business combination agreement with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the "Transaction") all of the issued and outstanding common shares of ESSA (the "Common Shares"), the Company intends to apply to the Supreme Court of British Columbia (the "Court") on August 5, 2025 for (i) an interim order authorizing the holding of a special meeting to consider and approve the Transaction (the "Interim Order") and (ii) for an order authorizing the Company to make an initial cash distribution to its shareholders prior to the closing of the Transaction (the "Distribution Order" and together with the Interim Order, the "Orders").

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating ESSA Pharma Inc. (NASDAQ: EPIX ) related to its sale to Xeno Acquisition Corp. Upon completion of the transaction, ESSA shareholders will receive a cash payment per share to be calculated based upon ESSA's cash balance at closing minus transaction costs, liability and legal exposure review, and a $4 million transaction fee payable to Xeno. Additionally, ESSA shareholders are entitled to receive one non-transferable contingent value right per share entitling them to future payments based on (i) up to $150,000.00, less any remaining liabilities and expenses not deducted at closing; and (ii) up to $2.8 million, less legal and other expenses incurred after closing. Is it a fair deal?